

A Message to the CLL/SLL Patient Community

From Newave Pharmaceutical Inc. (Lupeng Pharma) — May 2026

If you or someone you love has been living with **chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)** and your cancer has come back after treatment with a targeted therapy called a **BTK inhibitor** (such as ibrutinib, acalabrutinib, zanubrutinib or orelabrutinib), we want you to know about **a new clinical trial evaluating a potential new treatment option**.

What Is the ROCKET-CLL Study?

ROCKET-CLL is an international clinical trial testing a new investigational drug called **rocbrutinib (LP-168)** against a currently approved treatment (pirtobrutinib), to see which works better for patients whose CLL/SLL has returned after prior covalent BTK inhibitor therapy.

In plain terms:

- 2 groups (1:1): half receive rocbrutinib, half receive pirtobrutinib — pirtobrutinib is already approved for CLL and rocbrutinib is investigational (not yet approved). Early studies suggest rocbrutinib may also work, but this trial is designed to confirm that.
- 2 pills by mouth, once a day — no infusions, no hospital stays required
- 306 patients across the US, China, Australia and EU countries
- Study drug and trial-related tests are provided at no cost to you

What Makes Rocbrutinib Different?

Rocbrutinib is a **next-generation (4th-generation) BTK inhibitor** designed to work even when the cancer has learned to resist older drugs. Think of it like a smarter key that can open a lock even after the lock has been changed.

What does the research show so far?

The findings below come from earlier-phase studies of rocbrutinib used alone, not from a direct head-to-head comparison with pirtobrutinib. The ROCKET-CLL trial is designed to compare the two treatments. These results do not guarantee that rocbrutinib will perform similarly in the ROCKET-CLL trial.

- **About 78% of patients responded** to rocbrutinib even after their CLL came back following prior BTK therapy (results presented as an **oral presentation at ASH 2025**, one of two oral presentations rocbrutinib received at the 67th ASH Annual Meeting in Orlando).
- **After approximately 30 months of follow-up, patients could stay without disease progression for about 28 months.**
- **Even patients who had failed multiple prior treatments responded:** those who had been treated with both a BTK inhibitor and venetoclax (a BCL-2 inhibitor) showed an 80% response rate — this is especially meaningful for patients who feel their options may be limited.
- **The side effect profile was generally manageable in available data:** across more than 300 patients in US and China trials, no cases of serious irregular heartbeat were reported to date, and fewer than 1% of patients had to stop treatment due to side effects. This is a direct result of how selectively rocbrutinib targets the BTK protein without broadly hitting unrelated proteins that cause toxicities.

Who May Be Eligible?



You may qualify if you:

- Are 18 years of age or older
- Have been diagnosed with CLL or SLL
- Have previously been treated with a covalent BTK inhibitor (such as ibrutinib, acalabrutinib, zanubrutinib or orelabrutinib)
- Have NOT previously been treated with pirtobrutinib or a BTK degrader
- Are well enough to participate (your doctor will confirm based on your full history)

This trial may be especially relevant if you have already received multiple lines of therapy, including venetoclax — the early data show rocrutinib can still work in this setting.

How to Learn More or Find a Participating Site

The ROCKET-CLL trial is now enrolling at sites across the United States and globally. To find a site near you:

- **Visit ClinicalTrials.gov** and search [NCT07342478](https://clinicaltrials.gov/ct2/show/study/NCT07342478) or “ROCKET-CLL”
- **Ask your hematologist or oncologist** if this trial is right for you
- **Contact us:** ROCKET-CLL@newavepharma.com | www.newavepharma.com

We know that living with relapsed or refractory CLL/SLL is deeply challenging, especially if you have already been through multiple treatments. Our team is committed to bringing forward the most promising new medicines for this community, and we are grateful for the courage of every patient and family who considers participating in clinical research. Your participation makes future treatments possible — for you, and for others to come.

With hope and gratitude,

Newave Pharmaceutical Inc. (Guangzhou Lupeng)
ROCKET-CLL@newavepharma.com | www.newavepharma.com

This document is for informational purposes only and does not constitute medical advice. Please speak with your doctor to determine if this study is appropriate for you. Rocbrutinib is investigational and not approved for CLL/SLL. Discuss risks with your doctor. | ROCKET-CLL • NCT07342478